Performance Initiation Q4 17-18

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Patient Recruited?	Date of First Patient Recruited	Duration between VRA and NHS Permission	Duration between NHS Permission and First Patient	Duration between VRA and First Patient	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
17/LO/1656	229212	A PHASE III, OPEN-LABEL, MULTICENTER, TWO ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED BRAF WILD-TYPE MELANOMA	No		0	0	0	52			No		28/09/2017	20/11/2017	14/11/2017	03/01/2018	11/01/2018	Please Select...	11/01/2018							Y					Active screening was going on but no patient interested in consenting	Neither
17/SC/0242	222650	Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Intravenous FDY-5301 in Acute Myocardial Infarction (Protocol No. FDY-5301-201)	Yes	12/12/2017	0	0	0	11	85	96	No		13/03/2017	07/09/2017	06/09/2017	07/09/2017	18/09/2017	Please Select...	18/09/2017							Y					Acute STEMI study patients have to fit eligiblity, there were also issues with the randomised system and we lost 2 patients that had assented. We have randomised a further 2 patients this week	Neither
16/EE/0514	207302	Randomized, Double-Blind Phase 2/3 Study in Subjects with Malignant Pleural Mesothelioma with Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 with Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)	Yes	04/12/2017	0	0	0	167	40	207	No		20/01/2017	11/05/2017	28/02/2017	18/10/2017	25/10/2017	Please Select...	25/10/2017				Y			Y					Company sponsor changed during work up and budget contract from America 2 patients now on trial (Nov & Dec.)	Sponsor
16/SC/0439	199315	The ACL SNNAP Trial: ACL Surgery Necessity in Non Acute Patients. Comparison of the clinical and cost effectiveness of two management strategies for non-acute Anterior Cruciate Ligament (ACL) injury: Rehabilitation versus surgical Reconstruction.	Yes	08/12/2017	0	0	0	174	44	218	No		04/05/2017	04/05/2017	16/11/2016	03/10/2017	25/10/2017	Please Select...	25/10/2017				Y			Y					Delay in Contract Negotiations by sponsor, No suitable patients	Sponsor
17/EM/0059	221778	A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction(HFrEF).	Yes	31/10/2017	0	0	0	5	124	129	No		28/10/2016	24/06/2017	09/06/2017	21/06/2017	29/06/2017	Please Select...	29/06/2017				Y								Delay in Post Approval Amendment	Sponsor
17/SC/0142	215503	Evaluating the clinical and cost-effectiveness of permissive hypotension in critically ill patients aged 65 years or over with vasodilatory hypotension	Yes	18/10/2017	0	0	0	172	19	191	No		10/04/2017	10/04/2017	24/04/2017	08/08/2017	29/09/2017	Please Select...	29/09/2017				Y								Delays caused by sponsor	Sponsor
16/WS/0093	200488	(FAK-PD1) A Phase I/IIA study to assess safety, tolerability and preliminary activity of the combination of FAK (defactinib) and PD-1 (pembrolizumab) inhibition in patients with advanced solid malignancies	Yes	18/10/2017	0	0	0	116	58	174	No		13/04/2017	27/04/2017	25/04/2017	26/07/2017	21/08/2017	Please Select...	21/08/2017				Y			Y					Delays caused by sponsor|Eligible patients seen during the relevant period but did not consent to participate the trial	Sponsor
17/EE/0079	220827	A Randomized, double-blind, placebo-controlled, phase 3 study to evaluate the safety and efficacy of CCX168 in patients with anti-neutrophil cytoplasmic antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamise/ Azathioprine	Yes	21/02/2018	0	0	0	63	225	288	No		28/11/2016	09/05/2017	06/04/2017	05/07/2017	11/07/2017	Please Select...	11/07/2017				Y		Y			Y			Delays caused by sponsor|Rare or very rare disease|No eligible patients seen during the recorded period	Sponsor
17/YH/0120	208838	A pragmatic multi-centre randomised controlled non inferiority, cost effectiveness trial comparing injections of collagenase into the cord to surgical correction in the treatment of moderate Dupuytren?s Contracture in adult patients	Yes	31/07/2017	0	0	0	76	40	116	No		21/02/2017	06/04/2017	25/05/2017	21/06/2017	21/06/2017	Please Select...	21/06/2017	Y			Y								Delays caused by sponsor|Relevant permissions delayed and not granted in time	Sponsor
17/LO/2072	209317	Ways Back to Work. The occupational health management of NHS staff with mental health disorders: a feasibility study.	No		0	0	0	79			No		15/11/2017	04/12/2017	13/12/2017	21/02/2018	21/02/2018	Please Select...	21/02/2018				Y			Y					Difficult inclusion & Exclution Criteria, Now the study is recruited, Delay in Contract Negotiations	Sponsor
17/NE/0092	220929	A phase 3 C Difficile vaccine efficacy study - PF-06425090 for prevention of Clostridium difficile infection (CDI)	Yes	01/12/2017	0	0	0	0	120	120	No		12/12/2016	03/08/2017	28/03/2017	05/07/2017	03/08/2017	Please Select...	03/08/2017							Y					Difficult inclusion and exclusion criteria	Neither
17/EE/0377	222607	A double blind, placebo controlled, randomised dose escalation trial to investigate the safety and efficacy of topical salbutamol in the improvement of scar appearance when applied to approximated wound margins in healthy volunteers	Yes	15/01/2018	0	0	0	134	10	144	No		28/07/2017	24/08/2017	02/01/2018	05/01/2018	05/01/2018	Please Select...	05/01/2018				Y								Drug supply issues from sponsor contractor	Sponsor
16/NE/0279	198051	Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD)	No		0	0	0	142			No		06/03/2017	03/04/2017	29/09/2016	27/06/2017	23/08/2017	Please Select...	23/08/2017							Y					Eligible patients seen during the relevant period but did not consent to participate the trial	Neither
16/EE/0370	198596	MesoTRAP: A feasibility study comparing video-assisted thoracoscopic partial pleurectomy/decortication with indwelling pleural catheter in patients with trapped lung due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial.	No		0	0	0	33			No		24/02/2017	23/08/2017	11/01/2017	21/09/2017	25/09/2017	Please Select...	25/09/2017							Y					Eligible patients seen during the relevant period but did not consent to participate the trial	Neither
17/SC/0016	218645	A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable Pleural Mesothelioma	Yes	08/08/2017	0	0	0	18	102	120	No		10/03/2017	10/04/2017	16/03/2017	21/04/2017	28/04/2017	Please Select...	28/04/2017							Y					Eligible patients seen during the relevant period but did not consent to participate the trial	Neither
17/LO/0249	220398	A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN	Yes	25/09/2017	0	0	0	12	76	88	No		24/01/2017	29/06/2017	28/04/2017	22/06/2017	11/07/2017	Please Select...	11/07/2017							Y					Eligible patients seen during the relevant period but did not consent to participate the trial.	Neither
17/NW/0371	216207	A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade? (Infliximab) for the Treatment of Patients with Rheumatoid Arthritis	No		0	0	0	34			No		13/10/2016	15/08/2017	25/07/2017	15/08/2017	18/09/2017	Please Select...	18/09/2017				Y								First subject not recruited within 30 days due to delay with green light from sponsor	Sponsor

Performance Initiation Q4 17-18

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Patient Recruited?	Date of First Patient Recruited	Duration between VRA and NHS Permission	Duration between NHS Permission and First Patient	Duration between VRA and First Patient	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
17/LO/0915	221191	PEMAGS: A Prospective fEasibility study of Minimal Access Gynaecological Surgery	Yes	28/08/2017	0	0	0	89	13	102	No		05/05/2017	18/05/2017	20/07/2017	15/08/2017	15/08/2017	Please Select...	15/08/2017	Y			Y							HRA initial letter 18/05/2017HRA approval letter re-issued 20/07/2017copy of CI responsibilities signed was returned on 15/08/2017	Sponsor
17/EM/0315	220334	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease	No		0	0	0	115			No		11/10/2016	08/08/2017	03/11/2017	22/05/2017	01/12/2017	Please Select...	01/12/2017							Y					Just to confirm that the first subject was consented to TRAIL-1 today but unfortunately failed screening on her lung function.The delay and failure to meet the 30 day deadline was due to the subject not wishing to start the study before Christmas and us having to wait for Sponsor Green Light before we could screen the subject.	Neither
17/EM/0063	213979	A Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinab (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission	No		0	0	0	53			No		10/08/2016	10/08/2017	27/04/2017	22/09/2017	02/10/2017	Please Select...	02/10/2017						Y						No eligible patients seen during the recorded period	Neither
17/WM/0308	226910	Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects with Cystic Fibrosis (CF) and New Onset Respiratory Tract Pseudomonas aeruginosa (PA) Infection/Colonization	No		0	0	0	159			No		02/08/2017	02/08/2017	09/10/2017	19/10/2017	08/01/2018	Please Select...	08/01/2018						Y						None of the children so far met the inculsion criteria .0	Neither
17/YH/0345	233852	A phase 3, randomised, multicentre study of subcutaneous vs intravenous administration of daratumumab in subjects with relapsed or refractory multiple myeloma	No		0	0	0	60			No		03/11/2017	18/01/2018	17/01/2018	15/03/2018	19/03/2018	Please Select...	19/03/2018						Y						None of the children so far met the inculsion criteria .0	Neither
17/EM/0412	234907	An adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients	No		0	0	0	35			No		12/10/2017	08/12/2017	04/12/2017	10/01/2018	12/01/2018	Please Select...	12/01/2018						Y						None of the children so far met the inculsion criteria .0	Neither
17/EM/0055	222279	A Randomized, Double-Blind, Placebo controlled, Parallel Group Study of Patiromer for the Enablement of Spironolactone Use for Blood Pressure Control in Patients with Resistant Hypertension and Chronic Kidney Disease: Evaluation of Safety and Efficacy (AMBER)	Yes	06/10/2017	0	0	0	0	127	127	No		29/11/2016	01/06/2017	02/05/2017	01/05/2017	01/06/2017	Please Select...	01/06/2017				Y								Post approval amendment delayed the first patient recruitment	Sponsor
17/WM/0011	219130	A Phase II, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy	No		0	0	0	1			No		30/03/2016	07/06/2017	19/04/2017	17/05/2017	08/06/2017	Please Select...	08/06/2017						Y		Y				Rare Disease	Neither
16/LO/1355	168344	InPACT trial- International Penile Advanced Cancer Trial (International Rare Cancers Initiative study)	No		0	0	0	14			No		16/12/2016	01/12/2017	11/10/2016	15/12/2017	15/12/2017	Please Select...	15/12/2017								Y				Rare Disease.	Neither
16/LO/1024	195085	Safety and efficacy of Belimumab After B cell depletion therapy in systemic LUPUS erythematosus	No		0	0	0	29			No		11/07/2017	09/01/2018	20/09/2016	21/12/2017	07/02/2018	Please Select...	07/02/2018								Y				Rare Disease.	Neither
17/LO/0065	219950	A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600 mutant melanoma	No		0	0	0	8			No		21/02/2017	26/09/2017	14/02/2017	26/09/2017	04/10/2017	Please Select...	04/10/2017						Y		Y				Rare or very rare diseaseNo eligible patients seen during the recorded period	Neither
17/NW/0292	223951	Phase 1b multi-indication study of anetumab ravtansine (BAY 94-9343) in patients with mesothelin expressing advanced or recurrent malignancies	No		0	0	0	15			No		13/06/2017	26/09/2017	27/07/2017	05/10/2017	11/10/2017	Please Select...	11/10/2017						Y						Screening going 1 patient consented (17/11/2017)but Ineligible - criteria failure / pre-screening failure.0	Neither
17/SC/0294	224828	Title: A Phase III Randomised Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Neoadjuvant Anthracycline/Nab-paclitaxel Based Chemotherapy Compared with Placebo and Chemotherapy in Patients with Primary Invasive Triple-Negative Breast Cancer	Yes	13/03/2018	0	0	0	32	141	173	No		10/02/2017	21/09/2017	02/08/2017	11/10/2017	23/10/2017	Please Select...	23/10/2017						Y						Screening going 1 patient consented but Ineligible - criteria failure / pre-screening failure.0	Neither
17/LO/1068	224973	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN ADULT MALE PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC, PREVIOUSLY UNTREATED, METASTATIC CASTRATE-RESISTANT PROSTATE CANCER	No		0	0	0	11			No		20/04/2017	20/10/2017	27/07/2017	20/10/2017	31/10/2017	Please Select...	31/10/2017						Y						Screening going 1 patient consented but Ineligible - criteria failure / pre-screening failure.0	Neither
17/SS/0052	196827	Early Valve Replacement guided by Biomarkers of Left Ventricular Decompensation in Asymptomatic Patients with Severe Aortic Stenosis	Yes	22/03/2018	0	0	0	41	51	92	No		04/07/2017	20/12/2017	17/06/2017	03/01/2018	30/01/2018	Please Select...	30/01/2018						Y						Screening going 2 patient consented but Ineligible - criteria failure / pre-screening failure	Neither

Performance Initiation Q4 17-18

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Patient Recruited?	Date of First Patient Recruited	Duration between VRA and NHS Permission	Duration between NHS Permission and First Patient	Duration between VRA and First Patient	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
17/LO/1427	216241	The effects of Calcium Channel Blockers or Angiotensin converting enzyme inhibitor/Angiotensin Receptor Blocker Therapy on Blood Pressure Variability following acute ischaemic Stroke (CAARBS): A Feasibility Trial	Yes	05/03/2018	0	0	0	14	82	96	No		01/09/2017	29/11/2017	25/09/2017	22/11/2017	13/12/2017	Please Select...	13/12/2017						Y				Screening going on, Difficult Inclusion and Exclusion critetia	Neither
17/LO/0023	215490	MUK nine b: OPTIMUM. A phase II study evaluating optimised combination of biological therapy in newly diagnosed high risk multiple myeloma and plasma cell leukaemia.	Yes	20/11/2017	0	0	0	13	76	89	No		13/03/2017	23/08/2017	30/03/2017	23/08/2017	05/09/2017	Please Select...	06/09/2017						Y				Screening going on, No suitable patients	Neither
17/EE/0022	221514	A PHASE II, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF MOXR0916 IN COMBINATION WITH ATEZOLIZUMAB VERSUS ATEZOLIZUMAB ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ARE INELIGIBLE FOR CISPLATIN-BASED THERAPY	No		0	0	0	36			No		17/02/2017	03/05/2017	22/02/2017	02/06/2017	08/06/2017	Please Select...	08/06/2017						Y				Screening going on, No suitable patients	Neither
17/LO/0782	227047	Placebo-Controlled Proof of Concept Study to Investigate ANB020 Activity in Adult Patients with Severe Eosinophilic Asthma	Yes	14/12/2017	0	0	0	29	93	122	No		15/02/2017	14/08/2017	23/06/2017	14/08/2017	12/09/2017	Please Select...	12/09/2017						Y				Screening going on, No suitable patients	Neither
17/EM/0275	227425	A Multi-center, Double-blind, Randomized, Three-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants	Yes	25/01/2018	0	0	0	40	93	133	No		20/07/2017	14/09/2017	13/09/2017	15/10/2017	24/10/2017	Please Select...	04/12/2017						Y				Screening going on, No suitable patients	Neither
17/EE/0081	219405	An open label, single arm safety study of OncoSil?, administered to study participants with unresectable locally advanced pancreatic adenocarcinoma, given in combination with FOLFIRINOX or gemcitabine+nab-paclitaxel chemotherapies.	No		0	0	0	9			No		07/04/2017	18/07/2017	08/05/2017	20/07/2017	27/07/2017	Please Select...	27/07/2017						Y				Screening ongoing. Niche population and tight criteria.	Neither
17/EM/0190	219055	A Phase 3b, Randomized, Active Comparator, Open-label, Multicenter Study to Compare the Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and to Glimepiride as Add-on Therapy to Metformin in Patients with Type 2 Diabetes	No		0	0	0	8			No		01/03/2017	28/09/2017	01/08/2017	03/08/2017	06/10/2017	Please Select...	06/10/2017				Y						study was terminated by sponsor early on 16 October 2017	Sponsor
17/EE/0221	223856	A Phase 2, 24-week, Randomized, Double-Blind, Placebo-Controlled, Mulitcenter Study, Followed by a 24-Week Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects with Idiopathic Pulmonary Fibrosis	No		0	0	0	14			No		07/02/2017	06/10/2017	14/09/2017	12/07/2017	20/10/2017	Please Select...	20/10/2017				Y						There are 4 patients awaiting to be consented with appointments in February and march. The delay by the sponsor for official invite letter since July 2017.	Sponsor
17/EM/0058	221776	A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF).	No		0	0	0	5			No		28/10/2016	24/06/2017	05/06/2017	21/06/2017	29/06/2017	Please Select...	29/06/2017						Y				tight inclusion, screening a lot of patients, UK is finding this hard.	Neither
17/WS/0072	221444	EDOXABAN VERSUS STANDARD OF CARE AND THEIR EFFECTS ON CLINICAL OUTCOMES IN PATIENTS HAVING UNDERGONE TRANSCATHETER AORTIC VALVE IMPLANTATION ? IN ATRIAL FIBRILLATION	No		0	0	0	18			No		11/05/2017	21/09/2017	06/06/2017	04/10/2017	09/10/2017	Please Select...	09/10/2017					Y	Y				Very tight inclusion, screened just under 50 patients. Green light not given until 10th Dec 2017, surgeons were off and not there is a back up of elevative patients	Sponsor
16/EM/0172	194491	Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes	Yes	09/01/2018	0	0	0	8	159	167	No		22/09/2016	26/07/2017	24/05/2016	30/05/2017	03/08/2017	Please Select...	03/08/2017						Y				We cannot recruit patients who actually have episodes of atrial fibrillation (AF) so we are looking at a group between normal rhythm and AF, at this point the number of people with episodes of AHRE is significantly smaller than we anticipated.As you can see from Edge we have finally managed to recruit one participant and of course hope to be able to improve but the patient numbers are not materialising.	Neither
16/SW/0256	188499	A Randomised, Controlled feasibility trial of Intraoperative Cell Salvage vs Donor Blood Transfusion in Ovarian Cancer Surgery (TICTOC)	Yes	20/11/2017	0	0	0	1	67	68	Yes		26/05/2017	13/09/2017	11/11/2016	13/09/2017	14/09/2017	Please Select...	14/09/2017											
16/EE/0183	199109	Efficacy and safety of BI 655064 in patients with active lupus nephritis	No		0	0	0	0			Within 70 Days		16/02/2017	20/02/2018	01/07/2016	15/02/2018	20/02/2018	Please Select...	20/02/2018											
16/NS/0094	206213	BioImpedance Spectroscopy to Maintain Renal Output: The BISTRO Trial	Yes	27/11/2017	0	0	0	6	12	18	Yes		15/11/2016	09/11/2017	04/10/2016	03/11/2017	15/11/2017	Please Select...	15/11/2017											
17/LO/0402	209419	A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1-SELECTED RENAL CELL CARCINOMA AT INTERMEDIATE TO HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY	Yes	18/07/2017	0	0	0	8	28	36	Yes		10/11/2016	12/06/2017	09/06/2017	13/06/2017	20/06/2017	Please Select...	20/06/2017											
16/SS/0153	211403	Cardiac Magnetic Resonance guided management of mild- moderate Heart Failure	Yes	17/07/2017	0	0	0	8	45	53	Yes		18/07/2016	25/05/2017	25/11/2016	02/03/2017	02/06/2017	Please Select...	02/06/2017											
16/NS/0106	212541	Reducing Asthma Attacks in Children using Exhaled Nitric Oxide as a biomarker to inform treatment strategy - a randomised trial (RAACENO)	Yes	14/08/2017	0	0	0	21	46	67	Yes		19/05/2017	08/06/2017	04/04/2017	05/07/2017	29/06/2017	Please Select...	29/06/2017											

Performance Initiation Q4 17-18

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Patient Recruited?	Date of First Patient Recruited	Duration between VRA and NHS Permission	Duration between NHS Permission and First Patient	Duration between VRA and First Patient	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
17/NE/0061	215780	CONVINCE - COLchicine for preventioN of Vascular Inflammation in Non-CardioEmbolic stroke) - a randomised clinical trial of low-dose colchicine for secondary prevention after stroke.	Yes	21/03/2018	0	0	0	12	29	41	Yes		01/12/2017	08/02/2018	25/07/2017	15/01/2018	20/02/2018	Please Select...	20/02/2018												
17/LO/0095	216048	A tailored, cognitive behavioural approach intervention for mild to moderate anxiety and/or depression in people with chronic obstructive pulmonary disease (COPD): A randomised controlled trial	Yes	14/06/2017	0	0	0	36	27	63	Yes		09/03/2017	12/04/2017	08/03/2017	26/04/2016	18/05/2017	Please Select...	31/05/2017												
17/LO/0085	216434	Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects with Dialysis-Dependent Chronic Kidney Disease (DD-CKD) (INNO2VATE ? CONVERSION)	No		0	0	0				Within 70 Days		30/01/2017	07/03/2018	21/02/2017			Please Select...													
17/SC/0607	217496	A randomised, controlled trial of the use of a dedicated ballooned intercostal drain	No		0	0	0	16			Within 70 Days		31/10/2017	13/02/2018	18/12/2017	01/03/2018	01/03/2018	Please Select...	01/03/2018												
17/SC/0083	218035	A Prospective, Randomized, Open Label, Multi-center Study of the Safety and Pharmacokinetics of Apixaban versus Vitamin K Antagonist or LMWH in Pediatric Subjects with Congenital or Acquired Heart Disease Requiring Chronic Anticoagulation for Thromboembolism Prevention	Yes	11/09/2017	0	0	0	0	18	18	Yes		10/01/2017	24/08/2017	07/07/2017	18/08/2017	24/08/2017	Please Select...	24/08/2017												
16/WM/0512	218042	A Phase 1, open-label, randomised, repeat dose parallel group study to evaluate the pharmacokinetics, safety and tolerability of ferric maltol at three dosage levels in paediatric subjects (aged 10-17) with iron deficiency (with or without Anaemia)	Yes	11/12/2017	0	0	0	3	25	28	Yes		01/09/2017	13/11/2017	23/02/2017	07/11/2017	16/11/2017	Please Select...	16/11/2017												
17/NE/0115	218417	Phase II study of Pirfenidone vs placebo in patients with fibrotic ILD that cannot be classified with moderate or high confidence into any other category of fibrotic IP by Multidisciplinary Team (MDT) review (?unclassifiable? ILD).	Yes	16/08/2017	0	0	0	3	58	61	Yes		31/05/2017	16/06/2017	26/05/2017	06/06/2017	19/06/2017	Please Select...	19/06/2017												
17/LO/0035	218519	Development and evaluation of an intervention to support Adherence to treatment in adults with Cystic Fibrosis. A randomised controlled trial and parallel process evaluation.	Yes	08/02/2018	0	0	0	16	36	52	Yes		20/01/2017	18/12/2017	03/04/2017	16/10/2017	03/01/2018	Please Select...	03/01/2018												
17/LO/0041	219676	CardioMEMS OUS	Yes	22/11/2017	0	0	0	4	36	40	Yes		23/01/2017	13/10/2017	06/03/2017	17/08/2017	17/10/2017	Please Select...	17/10/2017												
17/EE/0177	220722	A Phase 3 Randomized, Controlled, Open-Label Study of Selinexor, Bortezomib, and Dexamethasone (SVD) Versus Bortezomib and Dexamethasone (VD) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)	Yes	26/02/2018	0	0	0	2	46	48	Yes		31/08/2017	09/01/2018	24/07/2017	21/12/2017	11/01/2018	Please Select...	11/01/2018												
17/EM/0156	220947	A Randomised Controlled Trial to Investigate the Use of High Frequency Airway Oscillations as Training to Improve Dyspnoea in COPD	Yes	04/07/2017	0	0	0	49	20	69	Yes		10/02/2017	26/04/2017	12/06/2017	17/03/2017	14/06/2017	Please Select...	14/06/2017												
17/EE/0481	226412	Pre-Implantation Trial of Histopathology In renal Allografts (PITHIA)	No		0	0	0	15			Within 70 Days		29/08/2017	23/01/2018	18/01/2018	07/02/2018	07/02/2018	Please Select...	07/02/2018												
17/EM/0166	222665	AVAIL-T: A Phase 2a trial of Avelumab, an anti-PDL1 antibody, in relapsed and refractory peripheral T-cell lymphoma (PTCL)	Yes	08/12/2017	0	0	0	6	29	35	Yes		13/04/2017	03/11/2017	30/06/2017	02/11/2017	09/11/2017	Please Select...	09/11/2017												
17/WS/0184	222904	The effects of an 8-week vegan diet on Trimethylamine-N-Oxide (TMAO) levels and post-challenge glucose levels in individuals with dysglycaemia..	Yes	17/10/2017	0	0	0	26	13	39	Yes		03/08/2017	08/09/2017	08/09/2017	04/10/2017	04/10/2017	Please Select...	04/10/2017												
17/WS/0071	224151	An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Dapagliflozin on the Incidence of the composite of =40% sustained reduction in eGFR, entering ESRD, CV or Renal Death in patients with Albuminuria and Moderate to Severe Renal Impairment (CKD 3-4)	Yes	11/12/2017	0	0	0	24	35	59	Yes		09/02/2017	13/10/2017	22/05/2017	25/10/2017	06/11/2017	Please Select...	06/11/2017												
17/LO/0504	224298	An open-label, single arm, repeat dose, multi-centre study to evaluate the use of an autoinjector for the subcutaneous administration of mepolizumab in subjects with severe eosinophilic asthma	Yes	04/08/2017	0	0	0	8	43	51	Yes		10/04/2017	14/06/2017	15/05/2017	12/06/2017	22/06/2017	Please Select...	22/06/2017												
17/WM/0219	224822	A feasibility study considering the use of the STAK Tool in addition to standard physiotherapy compared to standard physiotherapy alone to treat arthrofibrosis patients following total knee replacement.	Yes	02/08/2017	0	0	0	49	2	51	Yes		22/05/2017	12/06/2017	18/07/2017	31/07/2017	31/07/2017	Please Select...	31/07/2017												
17/SC/0391	227067	The High-volume Haemodiafiltration vs High-flux Haemodialysis Registry Trial	Yes	19/03/2018	0	0	0	12	7	19	Yes		22/11/2017	28/02/2018	07/09/2017	09/02/2018	12/03/2018	Please Select...	13/03/2018												
17/EE/0255	227279	A DOUBLE-BLIND, RANDOMISED, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF THREE DOSES OF ORVEPITANT IN PATIENTS WITH CHRONIC REFRACTORY COUGH	Yes	01/11/2017	0	0	0	5	58	63	Yes		10/04/2017	30/08/2017	26/07/2017	22/08/2017	04/09/2017	Please Select...	04/09/2017												
17/EE/0264	228153	POSEIDON - A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non-Small-Cell Lung Cancer (NSCLC)	Yes	09/01/2018	0	0	0	1	56	57	Yes		16/06/2017	13/11/2017	12/09/2017	09/11/2017	14/11/2017	Please Select...	15/11/2017												

Performance Initiation Q4 17-18

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Patient Recruited?	Date of First Patient Recruited	Duration between VRA and NHS Permission	Duration between NHS Permission and First Patient	Duration between VRA and First Patient	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
17/LO/1451	229939	A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Alone or in Addition to Oral Antidiabetes Drugs (OADs)	No		0	0	0	0			Within 70 Days		03/07/2017	20/02/2018	24/01/2018	29/01/2018	20/02/2018	Please Select...	20/02/2018											
17/SW/0207	231037	Fractional Flow Reserve Derived from Computed Tomography Coronary Angiography in the Assessment and Management of Stable Chest Pain.	No		0	0	0				Within 70 Days		03/10/2017	07/03/2018	03/10/2017			Please Select...												
17/EE/0361	231209	A 2-treatment epoch, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma	Yes	08/11/2017	0	0	0	0	7	7	Yes		15/09/2017	01/11/2017	31/10/2017	09/10/2017	01/11/2017	Please Select...	01/11/2017											
17/EM/0367	231327	A multi-centre, open-label extension, safety study to describe the longterm clinical experience of mepolizumab in participants with hypereosinophilic syndrome (HES) from Study 200622	Yes	22/12/2017	0	0	0	18	18	36	Yes		06/09/2017	16/11/2017	10/11/2017	27/11/2017	04/12/2017	Please Select...	04/12/2017											
17/NW/0517	232120	Effectiveness and cost of integrating a protocol with use of liraglutide 3.0mg into an obesity service (STRIVE Study)	Yes	28/11/2017	0	0	0	27	7	34	Yes		10/08/2017	25/10/2017	16/10/2017	14/11/2017	21/11/2017	Please Select...	21/11/2017											
17/EE/0040	222216	Emergency Cerclage in Twin pregnancies at Imminent Risk of Preterm Birth: an Open-Label Randomised Controlled Trial	No		0	0	0	1			Within 70 Days		05/12/2017	26/02/2018	02/03/2017	27/02/2018	27/02/2018	Please Select...	27/02/2018											
18/EM/0006	232310	The effects of reducing prolonged sitting bouts with regular light upright movement breaks on glucose regulation in individuals at high risk of or with type 2 diabetes.	Yes	08/03/2018	0	0	0	19	15	34	Yes		18/07/2017	02/02/2018	31/01/2018	21/02/2018	21/02/2018	Please Select...	21/02/2018											
16/LO/0680	186642	SMILE: Strategy for Maintenance of HIV suppression with elvitegravir+darunavir/ritonavir in children (PENTA 17). A two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety and antiviral effect of current standard antiretroviral therapy compared to elvitegravir (EVG) administered with darunavir/ritonavir (DRV/r) in HIV-1 infected, virologically suppressed paediatric participants.	No		0	0	0	2			Within 70 Days		27/11/2017	07/03/2018	28/07/2016	02/03/2018	09/03/2018	Please Select...	09/03/2018											
17/LO/1865	232414	Randomized, open label, multicenter study assessing the clinical benefit of isatuximab combined with carfilzomib (Kyprolis?) and dexamethasone versus carfilzomib with dexamethasone in patients with relapsed and/or refractory multiple myeloma previously treated with 1 to 3 prior lines	Yes	22/02/2018	0	0	0	4	41	45	Yes		09/10/2017	08/01/2018	13/12/2017	10/01/2018	12/01/2018	Please Select...	09/02/2018											
17/NE/0377	233847	A phase 3b, multicenter, prospective, randomized, double blind, placebo-controlled study to reduce the incidence of pre-dialysis hyperkalemia with Sodium Zirconium Cyclosilicate (DIALIZE)	No		0	0	0	34			Within 70 Days		10/10/2017	21/02/2018	19/02/2018	26/02/2018	27/03/2018	Please Select...	27/03/2018											
17/EM/0444	235251	Phase 1-2 study fo the safety, pharmacokinetics and preliminary activity of ASTX660 in subjects with advanced solid tumours and lymphomas.	No		0	0	0	12			Within 70 Days		24/11/2017	09/02/2018	05/02/2018	21/02/2018	21/02/2018	Please Select...	21/02/2018											
17/YH/0432	236091	A double blind (sponsor open) placebo-controlled, stratified, parallel group study to evaluate the efficacy and safety of repeat doses of GSK3772847 in participants with moderate to severe asthma with allergic fungal airway disease (AFAD).	No		0	0	0	26			Within 70 Days		06/10/2017	23/02/2018	19/02/2018	15/03/2018	21/03/2018	Please Select...	21/03/2018											